<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl1">
 <label>Table 1</label>
 <caption>
  <p>Nucleic acid derived vaccine candidates for COVID-19 in Clinical phase.</p>
 </caption>
 <alt-text id="alttext0025">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Vaccine candidate</th>
    <th>Current status</th>
    <th>Vaccine characteristics</th>
    <th>Developer</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>mRNA-1273</td>
    <td>Phase 1/Phase 2 (
     <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04283461" id="intref0095" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04283461</ext-link>)
    </td>
    <td>Lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine. Pre-fusion stabilized spike (S) protein of SARS-CoV-2</td>
    <td>Moderna</td>
   </tr>
   <tr>
    <td>INO-4800</td>
    <td>Phase 1 (
     <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/record/NCT04336410" id="intref0100" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04336410</ext-link>)
    </td>
    <td>DNA plasmid
     <break/>Vaccine encoding spike (S) protein delivered by Electroporation
     <break/>Device
    </td>
    <td>Inovio Pharmaceuticals</td>
   </tr>
   <tr>
    <td>ChAdOx1</td>
    <td>Phase 1/Phase 2 (
     <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04324606" id="intref0105" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04324606</ext-link>)
    </td>
    <td>Non-replicating viral vector</td>
    <td>University of Oxford</td>
   </tr>
   <tr>
    <td>Pathogen-specific-aAPC</td>
    <td>Phase 1 (
     <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04299724" id="intref0110" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04299724</ext-link>)
    </td>
    <td>Artificial antigen presenting cells (aAPCs) modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins</td>
    <td>Shenzhen Geno-Immune Medical Institute</td>
   </tr>
   <tr>
    <td>LV-SMENP-DC</td>
    <td>Phase 1 (
     <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04276896" id="intref0115" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04276896</ext-link>)
    </td>
    <td>Dendritic cells (DCs) modified with lentiviral vector expressing synthetic minigene based on domains of selected viral proteins; administered with antigen-specific cytotoxic T lymphocytes (CTLs)</td>
    <td>Shenzhen Geno-Immune Medical Institute</td>
   </tr>
   <tr>
    <td>Ad5-nCoV</td>
    <td>Phase 1 (
     <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04313127" id="intref0120" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04313127</ext-link>)
    </td>
    <td>Adenovirus type 5 vector that encodes S protein</td>
    <td>CanSino Biologicals</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>Reference: 
    <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="intref0125" xmlns:xlink="http://www.w3.org/1999/xlink">ClinicalTrials.gov</ext-link>.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
